Key Points
- Group Gp Lp Column III purchased 30,884 shares of Surrozen on Dec. 5 at an average cost of $19.54 ($603,473), increasing its holding to 981,890 shares (a 3.25% rise); the holder also bought 315,457 shares on Nov. 13 and 5,266 shares on Dec. 4, indicating notable insider accumulation.
- Surrozen is a clinical‑stage biotech with a market capitalization of $175.43M; the company reported a loss per share of $3.61 last quarter (missing estimates) and analysts forecast -8.49 EPS for the year, while the stock trades near $20 and carries an average rating of "Moderate Buy" with a $38.50 target.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey purchased 5,266 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were acquired at an average cost of $17.35 per share, for a total transaction of $91,365.10. Following the acquisition, the director owned 965,509 shares of the company's stock, valued at approximately $16,751,581.15. The trade was a 0.55% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Tim Kutzkey also recently made the following trade(s):
- On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, with a total value of $603,473.36.
- On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The stock was acquired at an average price of $12.65 per share, for a total transaction of $3,990,531.05.
Surrozen Price Performance
Shares of Surrozen stock opened at $20.47 on Tuesday. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $21.33. The business's fifty day moving average price is $14.07 and its two-hundred day moving average price is $11.41. The company has a market capitalization of $175.43 million, a P/E ratio of -0.92 and a beta of 0.62.
Surrozen (NASDAQ:SRZN - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have commented on the stock. Wall Street Zen upgraded shares of Surrozen to a "sell" rating in a research report on Friday, November 28th. Lifesci Capital upgraded shares of Surrozen to a "strong-buy" rating in a research note on Thursday, November 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $38.50.
Check Out Our Latest Stock Analysis on SRZN
Institutional Trading of Surrozen
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC lifted its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock valued at $277,000 after acquiring an additional 5,702 shares during the last quarter. Acuta Capital Partners LLC boosted its stake in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company's stock worth $2,299,000 after acquiring an additional 8,415 shares in the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock worth $2,736,000 after acquiring an additional 20,247 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Surrozen by 37.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company's stock worth $1,034,000 after acquiring an additional 24,000 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
